To test this directly, we used CRISPR-Cas9 to generate a loss of function of C4orf19 in MCF10A, which resulted in a proliferative advantage compared to control cells, consistent with it being a tumor-suppressor gene within chr4p (Figures 5A and S5A; STAR Methods). This evidence concerns the gene PGCKA1 and neoplasm.